BioWorld mentions BioChromix and BioChromix Pharma in an article
About disease-modifying treatment and molecular imaging for Alzheimer's. Read more (Link to BioWorld Today).
Article by Frost & Sullivan
Frost & Sullivan published an article in their Medical Diagnostics and Imaging Technology Alert the week of 08/20/2010.
Press release: BioChromix Pharma Read more (PDF).
STOCKHOLM – January 14, 2010. Karolinska Development AB (publ), and BioChromix AB announced today
the formation of BioChromix Pharma AB, a new company working to develop a novel Alzheimer treatment
with its unique knowledge of molecular chemistry.
BioChromix founds BioChromix Pharma
BioChromix Pharma is a company that will focus on the commercialization of novel pharmaceuticals for Alzheimer's disease.
BioChromix moves to Stockholm
BioChromix rents suitable laboratory in Stockholm and office space at Karolinska Institutet in Stockholm, Sweden as a member of the prestigious
Karolinska Institute Science Park. In this way we have been able to have access to necessary labs and expertise, for example world leading
Alzheimer's researches, and equipment. The Company is also a member of Karolinska Institute Science Park.
BioChromix is also member of "UIC Business Accelerator" where the focus lies on the commercialization phase of the Company. UIC Business
Accelerator has a strong Life Science reputation and supports companies by providing business management increased knowledge, new insights
and a continued business development.
BioChromix releases InsulinQC™
InsulinQC™ is proud to release a unique kit for specific determination the level of pre-fibrillar to fibrillar insulin species. Gel and
fibril formation can occur biopharma production InsulinQC™ provides simple means to assay unwanted species. The high specificity and
sensitivity offers the possibility to detect very low levels of pre-fibrillar and fibrillar Insulin species.
BioChromix releases HistoFast™
BioChromix releases the HistoFast™ Amyloid and Prion staining kit for determination the presence of aggregated misfolded protein and amyloid
in cryosectioned or paraffin embedded tissue sections. HistoFast™ is based on BioChromix patented probes and are for "Research and
Development Use" and gives a very fast, complementary to other immunohistochemistry staining procedures.
BioChromix receives R&D funding from Vinnova
Out of 400 applications, BioChromix has been selected and awarded 400 000 SEK from the VINNOVA program Forska&Väx to finance their pre study
for upcoming research and development projects. BioChromix targets protein misfolding diseases and brings innovative bioassays to the market
based on the company's unique probes.
BioChromix expands: Recruits project manager (AD) and LCP development chemist
Recent successful development have resulted in a need to fill these positions. We welcome Anna Herland (PhD) and Leif Johansson (MSc) to our
BioChromix is investing more resources on our novel prion bioassays
Recent investments in this project the last year has led to new interesting discoveries and BioChromix will therefore increase our efforts
in the future. Our primary goal is to commercialize a diagnostic test for pathogenic prion within the next one to two years. We are also
looking for a collaboration partner within this project.
During production, samples can be removed at different points during the production and analyzed with BioChromix probes using a standard protocol.
Contact BioChromix if you have any question or interest in this beta testing program.
BioChromix announces that beta testing of our Insulin quality assay has begun
BioChromix initiates beta testing of an insulin quality probe that can be used to detect insulin fibrils at ultra low concentrations in many
different types of insulin solutions. BioChromix high quality probes are designed for quality control during small or large scale insulin
production. The probes can also be used for research and development of production methods, formulation and more.
2005Peter Nilsson received the price from Prof. Fred Cohen, University of California, San Francisco, USA, and other members of the jury were
Prof. Jeffery W. Kelly, The Scripps Research Institute, San Diego, USA, Prof. Jonathan Weissman, University of California, San Francisco, USA,
and Prof. Nancy Bonini, University of Pennsylvania, Philadelphia, USA.
Peter and Anna have used BioChromix technology in state-of-the-art applications and worked on the use of BioChromix polymer for the
detection of amyloid fibril formation in amyloidogenic proteins. The title of the poster was "Conjugated luminescent polyelectrolytes -
conformation sensitive optical probes for the detection of amyloid fibril formation".
The Swedish Society for Biochemistry and Molecular Biology is a Constituent Society of FEBS (Federation of European Biochemical Societies)
which is an Associated Organization to IUBMB (International Union of Biochemistry and Molecular Biology).
First Price Award goes to Peter Nilsson and Anna Herland
During the conference "Molecular aspects of misfolding diseases", hosted by the Swedish Society for Biochemistry and Molecular Biology, in
Linköping, Sweden, Peter Nilsson and Anna Herland were awarded first price for the best Poster at the Poster Exhibition.